Kurs
-7,50%
Likviditet
0,13 MSEK
Kalender
| Tid* | ||
| 2025-02-12 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2024-05-29 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-24 | - | Extra Bolagsstämma 2024 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2024-02-08 | - | Split REDW 100:1 |
| 2024-01-19 | - | Extra Bolagsstämma 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-28 | - | Årsstämma |
| 2023-05-10 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2023-05-09 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-10-31 | - | Kvartalsrapport 2022-Q3 |
| 2022-10-25 | - | Extra Bolagsstämma 2022 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-16 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-12 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2020-05-11 | - | Årsstämma |
| 2020-05-11 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2019-05-07 | - | Årsstämma |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-13 | - | Bokslutskommuniké 2018 |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | - | Årsstämma |
| 2018-05-30 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-26 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-16 | - | X-dag ordinarie utdelning REDW 0.00 SEK |
| 2017-05-15 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-11-24 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-30 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Redwood Pharma will be attending two of the leading international conferences in ophthalmology and biotechology during 2022. The goals of the conferences will be to explore partnering interest in the Company's two dry eye programs, RP501 and RP101, as well as explore development collaborations where the IntelliGel drug delivery platform can be used.
- ARVO (Virtual) - May 11-12
- BIO-Europe (Fall, Leipzig Germany) - Oct. 24 - 26
To set up a meeting with Redwood Pharma, please contact:
Martin Vidaeus - CEO, Phone: +46 70-232 29 29
Email: martin.vidaeus@redwoodpharma.com
RP501 - a differentiated therapy addressing a large market
RP501 has significant therapeutic and commercial potential as a next-generation first-line therapy to treat the majority of DED sufferer, including males and females of all ages. The global market was valued at US$2.3 billion in 2019 and expected to grow to US$2.9 billion by 2030 (Source: Transparency Market Research 2020). Today, DED sufferers turn first to artificial tears (saline eye drops) to provide temporary relief.
Regular eye drops are, however, quickly cleared from the front of the eye and need frequent reapplication, creating a need for products that stay longer on the eye and reduce the number of drops to provide daily relief.
RP501 (IntelliGel) was used as the vehicle (placebo control) in the RP101 Phase II clinical trial completed last year, and our data from the RP101 trial showed that twice daily administration of RP501 improved both symptoms and objective measures of DED, in post-menopausal women with severe disease. In this trial, RP501 demonstrated increased tear fluid production as measured by the Schirmer test. Likewise, it improved various symptoms including foreign body sensation and dryness. RP501, as an easy-to-apply alternative to artificial tears providing long-lasting relief with fewer instillations per day, may thus offer a convenient and differentiated solution to over 340 million people worldwide suffering from DED.